CORESTEMCHEMON Inc. (KOSDAQ: 166480)

Market Cap	237.29B
Revenue (ttm)	30.43B
Net Income (ttm)	-34.65B
Shares Out	21.97M
EPS (ttm)	-1,724.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,197
Open	11,000
Previous Close	11,110
Day's Range	10,450 - 11,280
52-Week Range	5,250 - 14,600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About CORESTEMCHEMON

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company was formerly known as Corest...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 355
• Stock Exchange: KOSDAQ
• Ticker Symbol: 166480

Financial Performance

In 2023, CORESTEMCHEMON's revenue was 33.66 billion, a decrease of -26.64% compared to the previous year's 45.88 billion. Losses were -17.67 billion, 682.9% more than in 2022.